A British coroner has determined that the cause of death for a 19 year old American student of law studying in England was a heart rhythm disorder. This is partly due to the weight loss medication tirzepatide.
Josephine Nasr was a University of East London student who died in Newham on 23 September 2025. According to Graeme Irvine the coroner of East London, Josephine Nasr’s death was due to a heart arrhythmia caused by myocardial bridging (a congenital disease) and an electrolyte balance caused by her low blood sugar because she was prescribed tirzepatide.
The Daily Mail reports that Nasr is a law student in her second year who received a prescription to buy the drug from California. When her body was discovered, the university staff found an empty vial. The New York Post, in reference to the article, said that Nasr was not obese, but overweight. The pathologist Alan Bates revealed the heart congenital disease which may cause arrhythmia during the autopsy. The inquest found that the nausea from tirzepatide can cause hypoglycemia. This, in turn causes electrolyte balance, leading to dangerous arrhythmia. Stress could also worsen the heart condition.
Bates says that Nasr was “a young woman who otherwise seemed healthy.” Josephine Nasr told her mother Lorin Mansour and sister Anastasia Nasr that, on the evening of her death at 8:30 pm, she was feeling nauseous. Her sister, worried that Josephine might become dehydrated, arranged to have her receive intravenous liquids through a private healthcare provider. However, Josephine did not respond to her attempts to reach her. She requested a check-up from the university.
A nurse and security staff found her on the floor of the bathroom. London Ambulance Service’s paramedic declared the woman dead on scene.
Tirzepatide works on GIP receptors and glucagon like peptide 1. Zepbound is used for obesity and sleep apnea. Mounjaro is for Type 2 Diabetes. This medication can have serious side effects, including nausea and vomiting.
Eli Lilly and Co. is the company that manufactures these medications. They state the drugs are approved only for serious illnesses and not cosmetic weight loss. It also states that these drugs are not for use by patients younger than 18 and do not endorse their use for any other purpose. The prescribing instructions for Mounjaro in the U.S. include severe gastrointestinal side effects among their warnings.
Nasr was a young, active woman, who enjoyed traveling, caring for others, and loved to travel. Her family is Coptic Christians. Her father told the court that she was always putting others before herself.

POMPANO (VINnews).- According to doctors, a 79-year old Pompano Beach resident with Alzheimer’s has cleared the amyloid from his brain following a treatment of a new antiamyloid drug for a year-and-a-half.
Join Our WhatsApp Group
Subscribe to Daily Roundup Email
Scott Milinsky is the second Florida resident to receive treatment using Kisunla. This drug, developed by Eli Lilly, targets amyloid, a characteristic of Alzheimer’s. Under the supervision of Dr. Hazel Wiley, he received 18 infusions spread over 18 months.
The plaques disappeared after a final PET scan.
Milinsky stated, “I was stunned.” “I sat down and said, Oh my God. I had no idea what to do. I felt so grateful. I felt so, grateful. I felt so happy. “It was overwhelming”
Milinsky is a grandparent who said that the diagnosis brought painful memories to his mind of the death of his father from the same illness.
All of it came flooding back. “I’m going to be like my dad,” he said. What a mess. “It’s frightening to die in that manner, without knowing who you are.”
Kisunla slows the progression of Alzheimer’s disease by removing and breaking down amyloid deposits.
Wiley explained that the substance “makes its way into the brain, where it breaks down and removes amyloid plaque.” By removing the amyloid plaque, we can see the benefits of a slowed cognitive decline.
Wiley warned that this treatment was not a cure, as it did not target tau tangles – another characteristic of the condition. She called the results important.
“It’s exciting. She said, “It’s both emotional and exciting at the same.” It’s great to finally see a benefit. To see that something is actually making a positive difference. For many years we didn’t have much.
Milinsky called the result a “turning point”.
He said: “This is the beginning of a new era in technology. There will be many more.” This is only the beginning.
Broward Health North’s Memory Disorder & Alzheimer’s Center is treating more than 60 patients.

A new study indicates that severe COVID-19 could reactivate dormant virus in the body.
More than 200,000 samples of biological material collected in a year by researchers from Boston Children’s Hospital, along with collaborators from 20 other biomedical hospitals located across the U.S., Canada and Ontario.
According to the Nature journal study, 11 dormant virus strains reactivated in the first forty days following hospitalization for SARS CoV-2 (the virus that causes COVID-19).
The reactivated virus included Epstein-Barr, Cytomegalovirus, Herpes Simplex Virus-1, and Anelloviridae – a virus family that does not appear to cause human diseases.
In healthy people, these viruses are usually inactive. However, they can become active during times of stress or illness.
The study concluded that reactivation of Anelloviridae virus, which is carried by the majority of adults, can lead to long-term disability, as well as long COVID. This condition occurs when the patient still has symptoms four weeks or more after infection.
The researchers also discovered that Epstein-Barr and cytomegalovirus reactivated in response to inflammation, rather than immunity suppression. This suggests a previously unknown mechanism for viral reactivation when severe illness occurs.
Ofer Levy is the co-author of the study and the director at Boston Children’s Hospital’s Precision Vaccines Program. He said he was surprised with the findings.
It was unknown to such a degree and extent how viral reactivation, i.e. The “waking up” of non-SARS CoV-2 viruses in the body, such as Herpes virus (such as those that are found in herpes), and their replication could be associated with severity and outcomes for COVID.
Researchers could use the findings to better understand COVID long and develop future diagnostic tests.
The findings of the study may not be applicable to milder or more moderate COVID-19 infections, as the study included only hospitalized COVID-19 patients.
The study showed that viral reactivation is associated with severe COVID-19 but did not prove that the reactivated virus causes long COVID.
Levy stated that the results raise the possibility of reactivation by other viruses contributing to COVID-19, however that further studies are required.
Dr. William Schaffner is a professor at Vanderbilt University Medical Center, Nashville. He was involved with the study. According to ABC News, the new study raised more questions than answers, and more research would be needed before determining if the findings were noteworthy.
Schaffner, in an ABC News statement said: “The authors do not attribute any diseases (including COVID long-term) to the [reactivated virus].” It is unclear whether the viruses play a role in the production of disease; it could be purely coincidental.
Levy said that more research is required to determine whether anelloviruses – which are traditionally considered to be harmless – can cause disease.
Levy stated that “despite the end of the SARS pandemic, SARS-CoV-2 still causes infections which have both acute (short COVID) and long-term consequences (“long COVID”),” It is estimated that 50,000 Americans could die of COVID between 2025 and 2026, while up to 10,000,000 Americans might have had long COVID the year before.
He continued, “Immunization is very important for vulnerable groups such as elderly adults to prevent severe consequences.” We continue to research COVID in order to prevent disease.
Onaola Adedeji is a physician who specializes in Family Medicine, Obstetrics, and Lifestyle Medicine. She also belongs to the ABC News Medical Unit.

Marla Miller-Wilson has worked in the background of clinical trials for 30 years. She helped biotechnology companies and pharmaceutical firms operationalize their research on a variety of cancers.
She was on the opposite side of her life when she turned 54.
Mills-Wilson stated, “I felt as though my whole life flashed in front of me when I was sitting there.”
The Youngsville mom of two, who has been diagnosed with pancreatic carcinoma last year. Her mother, who died at the age of 73 from this disease, also suffered.
She said, “Not only was my mother a pancreatic cancer patient who passed away but my father has stage 4 prostate cancer.” Both of my grandmothers died of cancer.
Mills-Wilson’s first response when asked about her initial thoughts after receiving her diagnosis was “Am I going end up like my mom?”
It’s difficult,” she continued. “It’s hard.” She continued. “I felt as if I was unable to think straight.”
Mills-Wilson told her doctors about her family’s history at each appointment. She also made sure to keep up with her regular physicals and saw a gastroenterologist, as well as undergo genetic testing.
It was still not screening which led to the doctors discovering her pancreatic carcinoma. The subtlest symptom was amber colored urine.
Mills-Wilson initially wondered if she had an infection or was dehydrated. After visiting an urgent care clinic, her low heart rate was a concern. She ended up in the emergency department.
Mills-Wilson has been diagnosed with locally advanced stage 2 pancreatic carcinoma. The tumor, she said, was wrapped around her blood vessels and initially prevented her from having surgery.
Mills-Wilson was “patient 1” of a UNC separate clinical trial. She received as part her treatment a drug that is being tested on patients with pancreatic carcinoma. After six months of chemo, the tumor had stopped wrapping around her vessels. She underwent Whipple Surgery.
After participating in her own clinical trial, Mills Wilson encourages other North Carolinians who are also cancer patients to take part in the research which could change the way cancers such as hers can be detected.
UNC Lineberger Comprehensive Cancer Center seeks 2,000 North Carolina residents to participate in the Vanguard Study. This is a clinical trial that evaluates blood-based test designed to detect multiple cancer types at one time.
Researchers are hoping that the study can help them answer a bigger question. Could routine blood draws help doctors detect cancers for which there is no screening test?
What is Vanguard Study?
Dr. Carrie Lee is a thoracic oncologist at UNC Lineberger Comprehensive Cancer Center and the chief medical officer of clinical research. She was one of the principal investigators for the NCI sponsored Vanguard Study.
Lee clarified that there are currently evidence-based guidelines for screening four types of cancers: colorectal, cervical, lung and breast cancer. Other deadly cancers, such as pancreatic and ovarian cancers, do not currently have screening procedures.
Lee stated that the goal of this study is to test novel methods for screening cancer.
Vanguard Study evaluates a more recent screening technique known as MCDs (multi-cancer assays). The blood-based test is designed to detect multiple types of cancers simultaneously, unlike traditional cancer screening tests.
Lee explained that the coolest thing about these is they’re based on blood. They are tubes of blood which can be easily drawn. This is used for screening multiple cancers simultaneously.
Vanguard Study evaluates two multi-cancer assays. The Vanguard Study randomly assigns participants to three different groups. Two of the groups use MCD tests, and the third is a control.
Lee explained that any participant assigned to a group receiving the MCD test will receive a positive signal. This information is then sent to them and their physician so they can have additional tests.
The researchers will track the progress of a cancer test that identifies an abnormality.
What happens to the patient with a multi-cancer assay positive? “How often do patients get cancer diagnosed?” Lee asked.
Each hub is working to enroll about 2,000 participants, bringing the Vanguard pilot study up to approximately 18,000 to 20,000 participants nationwide. The Vanguard Pilot Study will have approximately 18,000 – 20,000 participants across the country. Each hub is working on enrolling about 2,000 people. For some patients, this is really appealing because certain tests and procedures are associated with taking time off from work or other things. The goal is to find ways to screen multiple cancers simultaneously and make the process less burdensome for patients.
Lee warns, for now, that this is still a possible possibility being studied by researchers and not a medical practice. She said that people shouldn’t stop having their screenings such as Pap smears (Pap smears), CT scans, Mammograms, and colonoscopies.
Lee stated that the film was not yet ready to be viewed by the public. There’s a lot of promise but we do not want to overhype.
Lee says that there are no FDA approved multi-cancer assays at the moment, but some commercially are available, and cost between $700 and $1,000.
Lee stated that the results of Vanguard will probably inform a larger clinical study, which could involve around 200,000 participants.
Participants in North Carolina include:
Researchers at UNC are looking for adults aged 45 to 75 who haven’t been diagnosed with cancer in the last five years.
North Carolina’s hub, which aims to enroll 2,000 people by 2020, has already attracted more than 600 applicants. It expects that the enrollment period will continue for another year.
The researchers are trying to find participants that reflect North Carolina’s diversity, which includes people from outside of the Triangle area and those with different racial backgrounds and socioeconomic status.
Lee stated, “We are concerned that the results of the study will be applicable to the whole population.”
Participants do not have to go to Chapel Hill to complete some parts of the research.
The study requires blood collection at the start and then again after a year. Collection sites are available at UNC Health Southeastern, Chapel Hill and Hillsborough.
Vanguard Study can be contacted directly by those interested:
Email: LCCC_VanguardStudy@med.unc.eduPhone: (919) 843-4863
Care in the future: a new future
Mills-Wilson, who underwent a Whipple procedure and a clinical trial afterward, said that she was doing well. She returns to UNC for blood tests and scans every three months.
She hopes that by sharing her experiences, others will be inspired to take part in research of the same kind she spent a large portion of her career assisting with.
The Vanguard Clinical Trial is important. “No one wants cancer to be discovered,” said she. Early detection is key.
She also stressed that it is important to include people with diverse backgrounds in clinical studies.
She said that the more participants in cancer clinical trials, of any ethnicity, from all walks of life and backgrounds, the better.
Mills-Wilson’s message to those who might qualify for Vanguard is direct.
She said, “It’s easy to live our lives without understanding the implications.” Some people don’t understand the impact cancer can have on families. I would like to make everyone aware of the importance that clinical trials play in helping patients.
Mother added: “We need to get the whole community involved in this trial. We want them to contact UNC and find out if they qualify to take part.” “We need community participation.”
Mills-Wilson’s answer is that the issue has become more than a theoretical one.
She died a few months after her mother’s diagnosis of stage 4 pancreatic carcinoma. Her mother’s death was a result of stage four pancreatic cancer. She had herself been healthy and feeling well for months before her diagnosis.
Mills-Wilson is now thinking about the impact of earlier detection on her son, 21, and daughter, 15.
Who knows where this might lead or what it could mean? “It could lead to my son and daughter being able to get these earlier, rather than waiting to find out or later,” Mills Wilson said.
Lee believes that future researchers will be able to determine the feasibility of such research through studies like Vanguard.
Lee stated that “maybe there will be a better way of helping patients such as Marla understand their cancer earlier before it spreads or becomes a real threat to them life.”
Mills-Wilson encourages North Carolinians to consider taking part, not only for the potential learning they can gain but also for their future patient’s benefit.

You can now hear Fox News stories!
According to a new study led by NYU Langone Health, middle-aged adults can live an additional 13 years without dementia if they avoid smoking, high blood pressure and diabetes.
This study was published in Neurology Open Access. It analyzed health data over a long period of time to find out how cardiovascular fitness during midlife affects brain function several decades later.
According to research, reducing these three vascular risks between the ages of 48 and 68 can dramatically delay mental decline.
ALZHEIMER BLOOD TEST MAY BE ABLE TO PREDICT SYMPTOMS YEARS ADVANCE BUT EXPERTS WARN CAUTION
In a recent press release, Dr. Josef Coresh said, “Our results suggest that individuals should actively avoid these risk factors during midlife in order to preserve brain health over a period of more than a decade.”
He said that identifying ways to stop memory loss was vital. About 42% of Americans will develop dementia by the time they reach 55.
Data from an ongoing study that started in 1986, the Atherosclerosis Risk in Communities Study was reviewed. The study included more than 12000 participants who were free of dementia and had an average age of 56.
Doctor Says: POPULAR WEIGHT LOSS DRUGS MIGHT PROTECT FROM A DEATHLY DISEASE
Researchers tracked the health trajectory of subjects after screening them for elevated blood pressure, diabetes and smoking. This was done for 26 years on average.
At the end of this observation period, 3008 participants developed dementia while 5 238 people died with no cognitive impairment.
CLICK HERE TO DOWNLOAD FOX NEWS APP
This study showed a large gap in midlife health. Participants with all three conditions had an average of 30 years without dementia following baseline examinations. Those with three or more conditions had an average of 17 years until they developed dementia, and even less before dying.
The demographic trends reported were based on sexe and race. The cognitive health of female participants was longer than that of male participants regardless of their health.
Women with three or more risk factors survived on average 18.1 years before developing dementia, while men only lived 16.6.
Test Yourself with Our Latest Lifestyle Quiz
White participants who had all three risk profiles averaged 19,6 years of dementia-free life, compared to Black participants.
CLICK HERE FOR OUR HEALTH NEWSLETTER
Coresh expressed the hope that these data would motivate smokers to stop smoking, and that they will begin monitoring their cardiovascular health in late fortys.
They also noted that observational designs cannot be used to prove cause-and-effect.
CLICK HERE TO READ MORE HEALTH STORIES